BMS-813160

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBMS-813160
Drug Alias NameBMS-813160
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-C chemokine receptor type 2 antagonistsC-C chemokine receptor type 5 antagonists
TargetsC-C chemokine receptor type 5C-C chemokine receptor type 2
Therapy Area/IndicationsHyperplasiaDiabetic NephropathiesCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyWashington University School Of Medicine
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms +[6] 
Inactive IndicationsHyperplasiaDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A